BioUK Awards 2026 celebrate outstanding achievement and breakthrough innovations from across the Life Sciences. BioUK, the not-for-profit membership organization focused on catalyzing success in UK life sciences, today announced the winners of the 18th annual BioUK Awards following a ceremony hosted at the Royal Lancaster Hotel, London. Across 12 categories, including BioUK's 'Special Recognition Award', the evening celebrated outstanding achievements from individuals and companies from all corners of the life sciences. Winners of the BioUK Awards 2026. Image Credit: BioUK The winners of the 2026 BioUK Awards: * The Best Start-Up Biotech Company Award, sponsored by Milton Park, was awarded to U-Ploid Biotechnologies, who are developing a first-in-class therapeutic targeting age-related infertility * The Best Emerging Biotech Company Award, sponsored by Thermo Fisher Scientific, went to Mursla Bio, a leader in Extracellular Vesicle science on a mission to significantly improve outcomes for at-risk patients through the power of AI precision medicine * The Best Early Stage Medtech Company Award, sponsored by Penningtons Manches Cooper, was collected by Calla Lily Clinical Care, a clinical-stage women's health company developing an intravaginal drug-delivery platform targeting threatened miscarriage and IVF, with future applications across oncology, menopause, infection and live-biotherapeutics * The Most Transformative Healthtech Company Award was won by Huma Therapeutics, the operating system for AI in regulated healthcare, giving health systems and life-sciences companies the ontology, primitives, and regulatory engine to launch compliant software in weeks * The Most Impactful Deal Award, sponsored by Mills & Reeve, was presented to Bicycle Therapeutics, who through agreements with the NDA, UKNNL, and SpectronRx, have created the world's first end-to-end 212Pb radiopharmaceutical ecosystem spanning discovery and development to commercial supply * The BioSeed 'One to Watch' Award, sponsored by EY, was presented to Calla Lily Clinical Care, who achieved the double-header accolade of wining two categories * The Best Industry Support Partner Award, went to Weatherden, a global clinical development consultancy helping biotech and pharma realize the full potential of their science and investment * The Most Impactful CRO Award, sponsored by Gallagher, was presented to Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease * The Best Established Medtech Company Award, was won by Digostics who have developed and launched the world's only home test kit for performing the oral glucose tolerance test, OGTT, the gold-standard laboratory test for detecting diabetes * The Best Established Biotech Company Award, sponsored by Precision for Medicine, went to Oxford-based Sitryx Therapeutics who are pioneering immunometabolism - harnessing cell metabolism to restore immune balance and deliver lasting remission for patients with chronic autoimmune and inflammatory disease * The Emerging Life Sciences Entrepreneur of the Year Award, sponsored by Informa, went to Stephanie Annett, Senior lecturer and Principle Investigator at RCSI University of Medicine and Health Sciences and interim CEO of ImuPhile, a university pre-spinout company * The Special Recognition Award, was presented to Professor Matthew Wood, whose exceptional scientific achievements, entrepreneurial vision and commitment to patients have helped shape the future of the UK life sciences sector and advance the global fight against rare diseases, which affect more than half a billion people worldwide On behalf of the BioUK community, I would like to take the opportunity to congratulate all of last night's finalists and winners. The BioUK Awards bring together the very best of the UK life sciences, and this year's finalists truly reflect the innovation, determination and scientific rigor that make its sector a leading voice on the global stage. Thank you to everyone who has supported this year's program, allowing AZoLifeSciences to recognize and celebrate the amazing science that is helping to bring real benefit to patients across the world." Stuart Rose, CEO, BioUK BioUK warmly congratulates the winners and everyone shortlisted for their remarkable innovation and achievement. Be the first to rate this article

BioUK Awards 2026 celebrate outstanding achievement and breakthrough innovations from across the Life Sciences. Abingdon, UK, 22 October 2026: - BioUK, the not-for-profit membership organisation focused on catalysing success in UK life sciences, today announced the winners of the 18th annual BioUK Awards following a ceremony hosted at the Royal Lancaster Hotel, London. Across 12 categories, including BioUK's 'Special Recognition Award', the evening celebrated outstanding achievements from individuals and companies from all corners of the life sciences. The winners of the 2026 BioUK Awards: 1. The Best Start-Up Biotech Company Award, sponsored by Milton Park, was awarded to U-Ploid Biotechnologies, who are developing a first-in-class therapeutic targeting age-related infertility. 2. The Best Emerging Biotech Company Award, sponsored by Thermo Fisher Scientific, went to Mursla Bio, a leader in Extracellular Vesicle science on a mission to significantly improve outcomes for at-risk patients through the power of AI precision medicine. 3. The Best Early Stage Medtech CompanyAward, sponsored by Penningtons Manches Cooper, was collected by Calla Lily Clinical Care, a clinical-stage women's health company developing an intravaginal drug-delivery platform targeting threatened miscarriage and IVF, with future applications across oncology, menopause, infection and live-biotherapeutics. 4. The Most Transformative Healthtech Company Award was won by Huma Therapeutics, the operating system for AI in regulated healthcare, giving health systems and life-sciences companies the ontology, primitives, and regulatory engine to launch compliant software in weeks. 5. The Most Impactful Deal Award, sponsored by Mills & Reeve, was presented to Bicycle Therapeutics, who through agreements with the NDA, UKNNL, and SpectronRx, have created the world's first end-to-end 212Pb radiopharmaceutical ecosystem spanning discovery and development to commercial supply. 6. The BioSeed 'One to Watch' Award, sponsored by EY, was presented to Calla Lily Clinical Care, who achieved the double-header accolade of wining two categories! 7. The Best Industry Support Partner Award, went to Weatherden, a global clinical development consultancy helping biotech and pharma realise the full potential of their science and investment. 8. The Most Impactful CRO Award, sponsored by Gallagher, was presented to Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease. 9. The Best Established Medtech Company Award, was won by Digostics who have developed and launched the world's only home test kit for performing the oral glucose tolerance test, OGTT, the gold-standard laboratory test for detecting diabetes. 10. The Best Established Biotech Company Award, sponsored by Precision for Medicine, went to Oxford-based Sitryx Therapeutics who are pioneering immunometabolism - harnessing cell metabolism to restore immune balance and deliver lasting remission for patients with chronic autoimmune and inflammatory disease. 11. The Emerging Life Sciences Entrepreneur of the Year Award, sponsored by Informa, went to Stephanie Annett, Senior lecturer and Principle Investigator at RCSI University of Medicine and Health Sciences and interim CEO of ImuPhile, a university pre-spinout company. 12. The Special Recognition Award, was presented to Professor Matthew Wood, whose exceptional scientific achievements, entrepreneurial vision and commitment to patients have helped shape the future of the UK life sciences sector and advance the global fight against rare diseases, which affect more than half a billion people worldwide. Reflecting on the 2026 BioUK Award programme, Stuart Rose, CEO, commented: "On behalf of the BioUK community, I would like to take the opportunity to congratulate all of last night's finalists and winners. The BioUK Awards bring together the very best of the UK life sciences, and this year's finalists truly reflect the innovation, determination and scientific rigour that make our sector a leading voice on the global stage. Thank you to everyone who has supported this year's programme, allowing us to recognise and celebrate the amazing science that is helping to bring real benefit to patients across the world." BioUK warmly congratulates the winners and everyone shortlisted for their remarkable innovation and achievement. For more information, please visit www.biouk-awards.com.

Bicycle Therapeutics (NASDAQ:BCYC) given new $14.00 price target at Needham & Company LLC. July 30, 2026 Key points. * Needham lowered its price target for Bicycle Therapeutics from $15 to $14 while maintaining a "buy" rating, implying substantial upside from the stock's prior close. The broader analyst consensus is "Hold," with an average target of $13.86. * Bicycle Therapeutics shares traded at about $4.00, near their 12-month low of $3.81, after the company reported a quarterly loss of $0.72 per share - worse than the $0.37 consensus estimate - and revenue of just $0.63 million. * Institutional ownership remains high at 86.15%, with GSK and Schroder Investment Management among recent new investors; meanwhile, CEO Kevin Lee sold shares primarily to cover tax obligations tied to vested equity awards. * MarketBeat previews top five stocks to own in August. Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) had its price objective cut by research analysts at Needham & Company LLC from $15.00 to $14.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Needham & Company LLC's target price suggests a potential upside of 249.56% from the stock's previous close. Several other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Morgan Stanley cut their price objective on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 8th. Wall Street Zen upgraded shares of Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, June 27th. Jefferies Financial Group restated a "buy" rating and issued a $12.00 target price on shares of Bicycle Therapeutics in a report on Thursday, April 30th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Bicycle Therapeutics in a research report on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $13.86. Bicycle Therapeutics price performance. Shares of Bicycle Therapeutics stock traded up $0.14 during trading on Thursday, hitting $4.00. 344,104 shares of the stock were exchanged, compared to its average volume of 428,018. The firm's 50-day moving average price is $4.21 and its 200 day moving average price is $4.95. The stock has a market cap of $279.59 million, a price-to-earnings ratio of -1.27 and a beta of 1.55. Bicycle Therapeutics has a 12-month low of $3.81 and a 12-month high of $9.16. Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.35). The business had revenue of $0.63 million during the quarter. Bicycle Therapeutics had a negative net margin of 344.95% and a negative return on equity of 35.74%. As a group, research analysts forecast that Bicycle Therapeutics will post -1.97 earnings per share for the current year. Insider transactions at Bicycle Therapeutics. In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total transaction of $25,214.35. Following the completion of the sale, the chief executive officer directly owned 605,408 shares of the company's stock, valued at $2,585,092.16. This represents a 0.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 9,977 shares of company stock valued at $42,702. Insiders own 22.00% of the company's stock. Institutional inflows and outflows. Institutional investors have recently modified their holdings of the stock. GSK plc acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth $10,829,000. Schroder Investment Management Group acquired a new position in Bicycle Therapeutics in the 4th quarter valued at $3,976,000. Renaissance Technologies LLC raised its position in Bicycle Therapeutics by 72.8% during the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company's stock worth $4,544,000 after buying an additional 412,700 shares during the last quarter. Woodline Partners LP purchased a new position in Bicycle Therapeutics during the 1st quarter worth $3,088,000. Finally, Birchview Capital LP lifted its stake in shares of Bicycle Therapeutics by 200.5% in the 4th quarter. Birchview Capital LP now owns 462,700 shares of the company's stock worth $3,276,000 after acquiring an additional 308,700 shares during the period. Institutional investors and hedge funds own 86.15% of the company's stock. Bicycle Therapeutics company profile. Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology. Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Bicycle Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list. While Bicycle Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.